PA Fasching
- Oncology top 10%
- Cancer Research top 5%
- Genetics top 10%
- Pulmonary and Respiratory Medicine top 10%
- Pharmacology top 5%
- Co-authors
- Michael P. LuxTanja FehmWerner SchrothHiltrud BrauchStefan WinterMichel EichelbaumGeorg HeinkeleWolfgang Simon
- Topics
- Advanced Breast Cancer Therapies (43 papers)Cancer Treatment and Pharmacology (30 papers)Breast Cancer Treatment Studies (30 papers)
- Cited by
- Cancer ResearchPharmacologyOncology
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
PA Fasching
86 papers receiving 940 citations
Peers
Comparison fields: 5 of 89
- Oncology 440
- Cancer Research 328
- Genetics 229
- Pulmonary and Respiratory Medicine 225
- Pharmacology 162
Countries citing papers authored by PA Fasching
This map shows the geographic impact of PA Fasching's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by PA Fasching with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites PA Fasching more than expected).
Fields of papers citing papers by PA Fasching
This network shows the impact of papers produced by PA Fasching. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by PA Fasching. The network helps show where PA Fasching may publish in the future.
Co-authorship network of co-authors of PA Fasching
This figure shows the co-authorship network connecting the top 25 collaborators of PA Fasching. A scholar is included among the top collaborators of PA Fasching based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with PA Fasching. PA Fasching is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 4 | |
| 3 | 33 | |
| 4 | 1 | |
| 5 | 3 | |
| 6 | 22 | |
| 7 | 1 | |
| 8 | 1 | |
| 9 | Phase III study of Ribociclib (LEE011) in combination with Fulvestrant for the treatment of postmenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who have received no or only one line of prior endocrine treatment : MONALEESA-3 | 3 |
| 10 | Integrative Medicine in Gynecologic Oncology - Possibilities and Limits Part 1 | 2 |
| 11 | 24 | |
| 12 | 18 | |
| 13 | 5 | |
| 14 | 26 | |
| 15 | 48 | |
| 16 | 1 | |
| 17 | 34 | |
| 18 | 81 | |
| 19 | 31 | |
| 20 | 33 |
About PA Fasching
PA Fasching is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 92 papers that have together received 969 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (43 papers), Cancer Treatment and Pharmacology (30 papers) and Breast Cancer Treatment Studies (30 papers). The work is most often cited by research in Cancer Research (328 citations), Pharmacology (162 citations) and Oncology (440 citations). PA Fasching has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Michael P. Lux, Tanja Fehm, Werner Schroth, Hiltrud Brauch, Stefan Winter, Michel Eichelbaum, Georg Heinkele, Wolfgang Simon, Matthias Schwab and M.W. Beckmann. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.